558 reports of this reaction
2.4% of all PEGASPARGASE reports
#6 most reported adverse reaction
SEPSIS is the #6 most commonly reported adverse reaction for PEGASPARGASE, manufactured by Servier Pharmaceuticals LLC. There are 558 FDA adverse event reports linking PEGASPARGASE to SEPSIS. This represents approximately 2.4% of all 23,600 adverse event reports for this drug.
Patients taking PEGASPARGASE who experience sepsis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEPSIS is a less commonly reported adverse event for PEGASPARGASE, but still significant enough to appear in the safety profile.
In addition to sepsis, the following adverse reactions have been reported for PEGASPARGASE:
The following drugs have also been linked to sepsis in FDA adverse event reports:
SEPSIS has been reported as an adverse event in 558 FDA reports for PEGASPARGASE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEPSIS accounts for approximately 2.4% of all adverse event reports for PEGASPARGASE, making it a notable side effect.
If you experience sepsis while taking PEGASPARGASE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.